title: Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
abstract: Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma. We evaluated the responses and survival times of 35 patients treated with VTD followed by MPT. All patients were newly diagnosed and non-transplantation candidates. Patients received six cycles of VTD, which were followed by eight cycles of MPT. Approximately 97% of patients exhibited early responses to therapy, as early as the second cycle of VTD. Thirty percent of the responses were high quality, which was defined as a complete response (CR), a near-CR or a very good partial response. High-risk patients were defined as patients with any of the following aberrations: del(13), t(4;14), or del(17p). The remaining patients were defined as standard risk. Eleven high-risk patients showed 100% response rates, including 91% high-quality responses. In contrast, 13 standard-risk patients exhibited 92% response rates, including 61% high-quality responses. The overall 2-year survival rates were 60% in high-risk patients and 85% in standard-risk patients, which was not significantly different. As a first-line therapy, VTD followed by MPT has the potential to provide high-quality responses with durable remission among elderly and high-risk patients (clinicaltrials.gov identifier: NCT00320476).
authors.affiliation: Hematology-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Goyang, South Korea.
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
authors.forename: Yeo-Kyeoung
authors.initials: YK
authors.lastname: Kim
authors.forename: Joo-Seop
authors.initials: JS
authors.lastname: Chung
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Kim
authors.forename: Jong-Youl
authors.initials: JY
authors.lastname: Jin
authors.forename: Young-Rok
authors.initials: YR
authors.lastname: Do
authors.forename: Suk-Joong
authors.initials: SJ
authors.lastname: Oh
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.forename: Chu-Myong
authors.initials: CM
authors.lastname: Seong
authors.forename: Chul Soo
authors.initials: CS
authors.lastname: Kim
authors.forename: Dong Soon
authors.initials: DS
authors.lastname: Lee
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D020360:Neoadjuvant Therapy / Q000379:methods; D011239:Prednisolone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D011239:Prednisolone; D008558:Melphalan